ABSTRACT. Inasmuch as recombinant human growth SMC, somatomedin C hormone is now more generally available for the treatment AP, alkaline phosphatase of different types of short stature, there is a need for better SDS-BA, standard deviation score for standing height calshort-term indicators of treatment success. In healthy chilculated according to bone age dren, serum concentrations of antigens related to the ami-SDS-CA, standard deviation score for standing height calnoterminal propeptide of type I11 procollagen (P-111-NP) culated according to chronological age closely follow the growth velocity curve. P-111-NP was SPSS, Statistical Package for the Social Sciences measured longitudinally in 20 children with growth hormone deficiency during 6 months of human growth hormone substitution therapy. Two different radioimmunoassay systems were used; one recognizes predominantly the intact propeptide showing a lesser affinity to a smaller monomeric peptide (RIAgnost assay), while the other assay detects both forms equally (FAB assay). These results were compared to the growth response [median 5.6 (0.4 to 13.9) cm in 6 months] and to other established growth correlated parameters (somatomedin C, alkaline phosphatase). A relatively better growth response correlated significantly with high pretreatment P-111-NP (RIAgnost assay) values ( r = 0.56) and delayed bone age ( r = -0.70).
A combination of these parameters in multiple regression analysis increased the cumulative prediction value to above 60% ( 3 = 0.61). On the other hand, P-111-NP (FAB assay) values proved to be best in monitoring treatment, correlating with the individual growth rate during the first 3 months ( r = 0.40; p < 0.05), during the consecutive 3 months ( r = 0.66; p < 0.001), and during the total 6-months period ( r = 0.46; p < 0.05). All other parameters showed associations to growth only during some treatment periods. Ease of measurement and good correlation with the growth response support the use of the P-111-NP determination in monitoring of human growth hormone therapy. (Pediatr Res 23: 167-171,1988) Abbreviations hGH, human growth hormone r-hGH, recombinant hGH GHD, growth hormone deficiency P-111-NP, amino-terminal\procollagen type I11 propeptide RIAgnost, radioimmunoassay for P-111-NP using complete antibodies against P-111-NP FAB, radioimmunoassay for P-111-NP using Fab antibody fragments against P-111-NP Short stature caused by inadequate secretion of pituitary hGH can be successfully treated by substitution with recombinant hGH which now is available in almost unlimited amounts for therapeutic use (1) . Numerous children with various forms of short stature are currently enrolled in clinical trials of hGH therapy (2), and factors predictive of hGH responsiveness as well as indicators of treatment success are being sought. Established parameters for short term monitoring of hGH therapy, i.e. somatomedin C (3,4) and alkaline phosphatase (5), often fail to correlate with growth. Measurements of height change give reliable results only after several months of treatment.
As collagen is the most important protein constituent of the extracellular matrix, collagen generation must be a prerequisite for normal growth. Precursor-specific segments of type-I11 procollagen, the major interstitial collagen, are cleaved in stoichiometric amounts during fibrillogenesis and various molecular species of the P-111-NP are released into serum (6) (7) (8) . Recently developed radioimmunoassay systems (9-1 1) allow study of the concentrations of these peptides in human body fluids during health and disease. When determined by molecular exclusion chromatography and radioimmunoassay, the intact triple stranded procollagen type I11 peptide (Col 1-3) and a smaller monomeric fragment (Col 1) represent the major P-111-NP serum antigens during growth (12) . In childhood P-111-NP levels vary with age (1 3, 14) correlating significantly with the growth velocity curve (15) . The possible use of P-111-NP measurements for the assessment of growth-related changes has been proposed recently (15) (16) (17) . We investigated 20 children with GHD before and during the first 6 months of treatment with recombinant hGH to elucidate the value of P-111-NP determinations compared to other well-established parameters, for predicting therapeutic success and for monitoring growth during hGH therapy.
MATERIALS AND METHODS
Patients. Twenty GHD children (1 1 male, nine female) were investigated after written informed consent was given by their parents. Auxological data before treatment is summarized in extracted hGH, but hGH therapy had been withdrawn after the risk of transmission of Creutzfeldt-Jacob's disease (1 8) became known. Seven patients were newly diagnosed.
Eight patients had complete and three had partial isolated idiopathic GHD; seven had multiple pituitary hormone deficiencies due to organic lesions, one had an empty-sella syndrome, and one had postradiation GHD. Patients with GHD after craniopharyngeoma were excluded from this study. Eleven patients with accompanying thyroid-stimulating hormone deficiencies and seven with partial ACTH deficiencies had received proper replacement therapy before the initiation of the study. Seventeen patients were prepubertal [stage I according to Tanner (19, 20) ], two were pubertal (stage 111, and IV, respectively), and one was fully mature (stage V).
Diagnosis of GHD. The diagnosis of GHD was made by demonstrating an inadequate hGH response after 1) administration of hGH-releasing factor (1-44) (1 &kg body weight, n = 20), 2) arginine infusion (0.5 g/kg body weight, n = 14), and 3) insulin-induced hypoglycemia (0.1 IU/kg body weight, n = 18). Basal serum hGH and somatomedin C levels were measured before treatment at 30-min intervals for 4 h during deep sleep and additionally every 2 h for a total of 24 h (n = 20). Complete GHD was diagnosed when hGH values did not exceed 5 ng/ml in any of these tests (except the GRF test). The three patients with partial GHD had an abnormal response in two tests but a spontaneous hGH secretion in the low normal range during 6 h of deep sleep (expressed as integral under the curve, according to Bierich (2 1); more than 2000 ng x min x ml-'). These patients also exhibited the highest basal SMC values and pretreatment growth rates. Exclusion of these three patients from the data analysis did not change the results. r-hGH from one of three different sources (Norditropin, Nordisk, Gentofte, Denmark, n = 14; r-hGH, Kabi-Vitrum, Munich, FRG, n = 3; Somatropin, Eli Lilly, Bad Homburg, FRG, n = 3) was administered by one daily subcutaneous injection of 2 IU/ m2 body surface at bedtime for 6 or 7 days/wk.
Standing height was measured with a stadiometer (Holtain Ltd., Crymmich, England). Heights and growth velocities were expressed as SDS according to Tanner et al. (22) and related to SDS-BA to permit comparisons in children with different stages of maturity. Bone age was determined by x-ray of the right wrist by the standards of Greulich and Pyle (22a).
Laboratory methods. Radioimmunoassays for serum P-111-NP were performed with two different assays. One was a commercially available antibody radioimmunoassay (RIAgnost) (RIAgnost P-111-P, Behringwerke AG, Marburg, FRG). Antibodies used in this kit recognize the intact propeptide (Col 1-3) and exhibit a 10-fold lesser affinity to Col 1 peptides (8, 10) . In addition we used a research version (generously supplied by Behringwerke AG) of this kit (FAB) using monovalent Fab antibody fragments that are equally reactive with Col 1-3 and Col 1 fragments (10). The intrassay variation for the RIAgnost assay was 11% and for the Fab modification was 6%. The respective interassay variations were 15 and 7%. Sensitivity of the RIAgnost assay was about 0.5 ng/ml and that of the FAB assay was about 5 ng/ml. Cross-reactivity of antibodies with other collagen types or fragments [type I procollagen, type I collagen, type IV collagen (NC1 and 7s domains)], or with Laminin P1 was less than 1%. Normal values are correlated to growth; values more than 40 ng/ml (RIAgnost) or 180 ng/ml (FAB) are seen occasionally in tall children during puberty (1 5) .
In adults values range between 3 to 13 and 9 to 97 ng/ml, respectively (23) .
Serum hGH concentrations were determined by radioimmunoassay as described by Quabbe (24) . SMC was measured in unextracted sera by a commercial kit (Nichols Institute Diagnostics, San Juan Capistrano, CA). AP was determined with a kinetic assay (Roche, Grenzach, FRG).
Statistical analysis. Statistical analysis was performed using the SPSS (25) with the Spearman correlation coefficient and the Mann-Whitney rank sum test. A multivariate regression analysis was used to define those variables exerting influences independent of others. This procedure also allowed the calculation of the relative importance (percent of overall predictive value) of the individual variables for predicting the increase in SDS-BA after 6 months. The total of 20 patients allows the evaluation of the predictivity of two variables showing the highest correlation.
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Ulml UII months months Fig. 1 . Mean values (and 1 SD) of the several monitoring parameters during treatment. Statistical differences between two consecutive measurements are indicated. AP was not determined after 3 days of treatment. All parameters showed significant increases with treatment. Corresponding to the lower median growth rate during the second treatment period P-111-NP values (RIAgnost and FAB) decline significantly after 3 months of treatment while no significant decreases were seen in SMC and AP.
RESULTS
Growth data. After 6 months of hGH treatment, patients showed increases in body height between 0.4 and 13.9 cm (median 5.6 cm) and an improvement in the SDS score for body length between 0.07 and 2.1 (median 0.93) for SDS-CA, and from 0.07 to 2.3 (median 1.03) for SDS-BA. Median growth was better during the initial 3 months 13.6 (0.3-3.2) cm] than in the following period 12.3 (0.1-4.9) cm].
No differences were observed between patients with different types of GHD or receiving different preparations of hGH. Sexual maturation or residual hGH secretion did not show a clear influence on growth response. The median growth was calculated to be 5.8 cm in the subgroups of the 17 prepubertal as well as in the 17 patients with complete GHD. In patients with partial GHD the two prepubertal patients showed average responses (4.9 and 5.8 cm) while the one patient in puberty (stage 111, bone age 14.5 yr) did not grow (0.4 cm). The growth responses of another pubertal patient (stage IV, bone age 14 yr; 6.7 cm growth) and the sexually mature patient (stage V, bone age 16 yr; 1.3 cm growth) with complete GHD were adequate regarding their growth potential.
Biochemical data. Significant increases of P-111-NP and SMC levels were seen after 3 days (p < 0.01) (Fig. 1) . While a further increase after 1 month was seen for P-111-NP ( p < 0.0 1) to values above those usually seen in healthy children, no further significant increase of SMC was observed. Although the individual courses varied, no mean rises were observed after 3 months except for AP. Levels of all parameters declined thereafter, correlating with the mean growth rate. P-111-NP values obtained with either assay correlated significantly with each other at all times during the course of treatment (r values were 0.85, 0.92, 0.61,0.80, 0.79 at 0, 0.1, 1, 3, and 6 months). Predictability of growth rate. Of those parameters determined before onset of therapy (Table 2) , only two proved to be associated with height increase after 6 months of therapy and seemed to have predictive relevance. Lower skeletal age (r = -0.70, p < 0.0 1) as well as higher P-111-NP (RIAgnost method) before therapy correlated with better growth (r = 0.56; p < 0.05) (Fig. 2) . Table 2 were included in a multiple regression analysis to study their eventual independent predictive value for growth as measured by the SDS-BA. While skeletal age exhibited the highest correlation, basal P-111-NP (RIAgnost) values prove to be the second most important variable independent from skeletal age. Combination of skeletal age and P-111-NP (RIAgnost) concentrations before therapy increases the correlation to growth rate (multiple r = 0.80). The cumulative prediction value rises above 60% (12 = 0.614). However, neither the initial increases of P-111-NP values (FAB or RIAgnost) after 3 days and 1 month nor measurements of SMC or AP correlated with growth after 6 months.
All variables listed in
Biochemical monitoring of hGH treatment. To investigate the use of P-111-NP (RIAgnost), P-111-NP (FAB), SMC, and AP serum determinations to monitor treatment, the values were correlated with growth in the respective intervals between determinations, (i.e. first and second 3 months). While basal P-111-NP (RIAgnost) levels seemed to have predictive value, those determined with the FAB method proved to be the better parameter for monitoring the success of hGH treatment. FAB serum levels correlated significantly with growth rate during the first 3-month period (r = 0.40, p < 0.05), the consecutive 3 months (r = 0.66, p < 0.01), or the total 6-month period (r = 0.46, p < 0.05). Other parameters showed a good correlation only during some periods: AP (r = -I-
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DISCUSSION
This study demonstrates that in GHD those patients with the most marked delay in bone maturation and those with normal collagen synthesis (as assessed by normal basal P-111-NP levels) may profit most from hGH treatment. Bone growth takes place in cartilagineous tissue but increased synthesis of supporting tissues also is necessary with type I11 collagen being the major interstitial collagen. Although type I11 collagen is absent in fully calcified bone it reappears during bone remodeling (26) . Therefore, determination of P-111-NP may give information about the activity of the connective tissue during growth. During situations of supernormal hGH secretion as in acromegaly (27) or of increased bone turnover as in Paget's disease (28) , adults exhibit elevated P-111-NP levels. These increased values return to normal during successful treatment (27, 28) .
P-111-NP serum antigens can be determined by two different methods. Although RIAgnost and FAB values correlate with each other, the methods give different information. The RIAgnost method recognizes predominantly the intact propeptide (Col 1-3) and may be more sensitive than FAB in reflecting unstimulated basal collagen metabolism. The good positive correlation between normal P-111-NP (RIAgnost) values before treatment and subsequent growth during treatment indicates that reasonably normal collagen synthesis may be a prerequisite for a satisfactory growth response to hGH. This is important in view of the fact that treatment with hGH is proposed also for diseases in which disturbances of connective tissue or bone metabolism are suspected (e.g. Turner's syndrome) (29) . Indeed low basal levels of P-111-NP are found in many patients with Turner's syndrome (1 5) suggesting, according to the above hypothesis, a poor growth response despite an eventually increased growth velocity at the onset of therapy (30) .
Carey et al. (31) assumed that high baseline values of type I procollagen in GHD predict a less than optimal response to growth hormone. These differences might be attributed to the fact that three of Carey's patients, with low basal type I procollagen values and good growth responses, suffered from organic hypopituitarism due to craniopharyngiomata. Such patients, for unknown reasons, may show good growth independent of hGH substitution (33). Furthermore, there was no correlation of basal type I procollagen levels with growth in 12 patients (r = -0.06), and normal values for type I procollagen or the relation of values to growth velocity in healthy children have not been determined.
On the other hand, we found, in accordance with Carey's observation, that treatment with hGH leads to a rise of serum collagen peptides that antedates measurable changes in body length. For better interpretation of results the exact relationship of these peptides to collagen synthesis and degradation have to be elucidated. The stimulation of collagen synthesis during hGH treatment is associated with increases in levels of type I (3 l), type I11 (12, 16) , and type IV (unpublished data) procollagen fractions in serum. P-111-NP immunoreactivity in serum increases most rapidly due to increases in both the intact propeptide (Col 1-3) , which is related to fibrillogenesis, and a smaller fragment (Col 1) (12). The FAB method detects both fragments equally and this may explain the better correlation of FAB serum levels with the hGH treatment response compared to results with the RIAgnost assay.
The good correlation of P-111-NP levels to the clinical response to hGH therapy suggests that the routine use of these assays for monitoring treatment with r-hGH may be useful. Up to now neither one of the presently available biochemical parameters alone nor the increase in growth velocity is totally reliable in predicting the success of hGH treatment after the short term.
Therefore, a combination of parameters as shown herein for P-111-NP and bone age may help to identify those patients likely to profit from hGH treatment.
